U.S. Markets closed

Is Catabasis Pharmaceuticals (CATB) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Catabasis Pharmaceuticals (CATB) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

Catabasis Pharmaceuticals is a member of the Medical sector. This group includes 842 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. CATB is currently sporting a Zacks Rank of #2 (Buy).

The Zacks Consensus Estimate for CATB's full-year earnings has moved 41.35% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

Based on the most recent data, CATB has returned 23.80% so far this year. In comparison, Medical companies have returned an average of 2.08%. This means that Catabasis Pharmaceuticals is outperforming the sector as a whole this year.

To break things down more, CATB belongs to the Medical - Biomedical and Genetics industry, a group that includes 345 individual companies and currently sits at #51 in the Zacks Industry Rank. This group has gained an average of 11.15% so far this year, so CATB is performing better in this area.

Investors in the Medical sector will want to keep a close eye on CATB as it attempts to continue its solid performance.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.